Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
3 reports, 3 independent
Updated Tue 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Merck announced its acquisition of Silence Therapeutics amid analyst rating changes.1 source
Analyst coverage initiated by Cantor Fitzgerald and Morgan Stanley regarding Silence Therapeutics.1 source
Keep exploring
The entities involved
-
Silence Therapeutics
UK business
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
-
Morgan Stanley
U.S. investment bank
Related events
- Briefing.com reported a rating change issued by Cantor Fitzgerald.
- Cantor Fitzgerald maintained a Buy rating on Meta.
- Multiple financial firms, including Cantor Fitzgerald and William Blair, issued rating updates and price targets for various stocks on August 10, 2026.
- Cantor Fitzgerald issued a neutral rating and price target, while Sherry Group Inc. significantly increased its share holdings on October 10, 2026.
- Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.